529 related articles for article (PubMed ID: 24584072)
1. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
[TBL] [Abstract][Full Text] [Related]
2. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
4. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
5. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
6. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
7. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
[TBL] [Abstract][Full Text] [Related]
8. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
[TBL] [Abstract][Full Text] [Related]
10. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.
Yashiro-Ohtani Y; Wang H; Zang C; Arnett KL; Bailis W; Ho Y; Knoechel B; Lanauze C; Louis L; Forsyth KS; Chen S; Chung Y; Schug J; Blobel GA; Liebhaber SA; Bernstein BE; Blacklow SC; Liu XS; Aster JC; Pear WS
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):E4946-53. PubMed ID: 25369933
[TBL] [Abstract][Full Text] [Related]
11. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
[TBL] [Abstract][Full Text] [Related]
12. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
13. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
14. NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
Dastur A; Choi A; Costa C; Yin X; Williams A; McClanaghan J; Greenberg M; Roderick J; Patel NU; Boisvert J; McDermott U; Garnett MJ; Almenara J; Grant S; Rizzo K; Engelman JA; Kelliher M; Faber AC; Benes CH
Clin Cancer Res; 2019 Jan; 25(1):312-324. PubMed ID: 30224339
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antileukemic therapies in
Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
[TBL] [Abstract][Full Text] [Related]
16. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
17. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.
Real PJ; Ferrando AA
Leukemia; 2009 Aug; 23(8):1374-7. PubMed ID: 19357700
[TBL] [Abstract][Full Text] [Related]
18. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
[TBL] [Abstract][Full Text] [Related]
19. BET inhibitor resistance emerges from leukaemia stem cells.
Fong CY; Gilan O; Lam EY; Rubin AF; Ftouni S; Tyler D; Stanley K; Sinha D; Yeh P; Morison J; Giotopoulos G; Lugo D; Jeffrey P; Lee SC; Carpenter C; Gregory R; Ramsay RG; Lane SW; Abdel-Wahab O; Kouzarides T; Johnstone RW; Dawson SJ; Huntly BJ; Prinjha RK; Papenfuss AT; Dawson MA
Nature; 2015 Sep; 525(7570):538-42. PubMed ID: 26367796
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]